Photo: 123RF
A treatment for Huntington's disease being trialled in New Zealand and Australia is showing promising early results, the US biotech company behind the drug says.
Skyhawk Therapeutics began trialling the novel drug, SKY-0515, on New Zealand and Australian patients a year ago and plans to expand globally.
Local disease advocates have described the treatment as a real hope.
Huntington's disease is a rare degenerative brain disorder with no cure at present, affecting about one in 10,000 people.
Continue Reading on RNZ
This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.